4794 T3D4739 Imipenem Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with cilastatin, a renal dipeptidase inhibitor. 74431-23-5 104838 C12H17N3O4S White powder. 1E+004 mg/L Imipenem is not effectively absorbed from the gastrointestinal tract and therefore must be administered parenterally. Imipenem acts as an antimicrobial through the inhibition of cell wall synthesis of various gram-positive and gram-negative bacteria. This inhibition of cell wall synthesis in gram-negative bateria is attained by binding to pencillin binding proteins (PBPs). In E. coli and selected strains of P. aeruginosa, imipenem has shown to have the highest affinity to PBP-2, PBP-1a, and PBP-1b. This preferential binding to PBP-2 and PBP-1b results in the direct conversion of the individual cell to a spheroblast, which leads to rapid cell lysis and death without filament formation. Renal. Half Life: 1 hour No indication of carcinogenicity to humans (not listed by IARC). For the treatment of bacterial infections caused by susceptible bacteria. 2014-09-11T05:14:11Z 2014-12-24T20:26:56Z Imipenem 471744 DB01598 true [H][C@](C)(O)[C@@]1([H])C(=O)N2C(C(O)=O)=C(C[C@]12[H])SCCNC=N C12H17N3O4S InChI=1S/C12H17N3O4S/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19)/t6-,7-,9-/m1/s1 InChIKey=ZSKVGTPCRGIANV-ZXFLCMHBSA-N 299.346 299.093976737 Exogenous Solid CHEMBL148 94631 <p>Maurizio Zenoni, &#8220;Imipenem production process.&#8221; U.S. Patent US20020095034, issued July 18, 2002.</p>